{
    "nct_id": "NCT03726879",
    "official_title": "A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer",
    "inclusion_criteria": "* Confirmed diagnosis of HER2-positive breast cancer, and hormonal and PD-L1 status, as documented through central testing of a representative tumor tissue specimen\n* Primary breast tumor size of > 2 cm by any radiographic measurement\n* Stage at presentation: T2-T4, N1-N3, M0 as determined by AJCC staging system, 8th edition\n* Pathologic confirmation of nodal involvement with malignancy must be determined by fine needle aspiration or core-needle biopsy. Surgical excision of lymph nodes is not permitted.\n* Patients with multifocal tumors are eligible provided at least one focus is sampled and centrally confirmed as HER2-positive.\n* Patients with multicentric tumors are eligible provided all discrete lesions are sampled and centrally confirmed as HER2-positive.\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Baseline LVEF >= 55% measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans\n* Adequate hematologic and end-organ function obtained within 14 days prior to initiation of study treatment\n* For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs\n* For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior history of invasive breast cancer\n* Stage IV (metastatic) breast cancer\n* Patients with synchronous bilateral invasive breast cancer\n* Prior systemic therapy for treatment of breast cancer\n* Previous therapy with anthracyclines or taxanes for any malignancy\n* Ulcerating or inflammatory breast cancer\n* Undergone incisional and/or excisional biopsy of primary tumor and/or axillary lymph nodes\n* Sentinel lymph node procedure or axillary lymph node dissection prior to initiation of neoadjuvant therapy\n* History of other malignancy within 5 years prior to screening, with the exception of those patients who have a negligible risk of metastasis or death\n* Cardiopulmonary dysfunction\n* Dyspnea at rest\n* Active or history of autoimmune disease or immune deficiency\n* Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab/placebo, 6 months after the final dose of doxorubicin, 12 months after the final dose of cyclophosphamide, 6 months after the final dose of paclitaxel, or 7 months after the final dose of trastuzumab, pertuzumab, or trastuzumab emtansine whichever occurs last\n\nExclusion Criteria Related to Trastuzumab Emtansine in the Adjuvant Setting:\n\n* Patients who achieved pCR\n* Evidence of clinically evident gross residual or recurrent disease following neoadjuvant therapy and surgery\n* Unable to complete surgery with curative intent after conclusion of neoadjuvant systemic therapy\n* Patient discontinued treatment with trastuzumab because of toxicity during the neoadjuvant phase of the study\n* Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, or sclerosis cholangitis\n* Patients with Grade >=2 peripheral neuropathy\n* Prior treatment with trastuzumab emtansine",
    "miscellaneous_criteria": ""
}